Literature DB >> 7522446

Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors.

S Soker1, D Goldstaub, C M Svahn, I Vlodavsky, B Z Levi, G Neufeld.   

Abstract

The binding of the 165 amino-acid form of vascular endothelial growth factor (VEGF165) to the VEGF receptors of vascular endothelial cells was potentiated by heparin and heparan-sulfate, but not by other glycosaminoglycans. Heparin fragments of 16-18 sugar units inhibited the binding of 125I-VEGF165 to VEGF receptors, while fragments larger than 22 sugar units potentiated the binding. Over-sulfated heparin was a better potentiator of 125I-VEGF165 binding than native heparin. O-desulfated and N-desulfated heparins potentiated the binding to a lesser extent than native heparin. Heparin and N-desulfated heparin efficiently inhibited the binding of 125I-VEGF165 to alpha 2-macroglobulin, but surprisingly, O-desulfated heparin was an ineffective inhibitor. Since alpha 2-macroglobulin does not bind heparin, it follows that VEGF165 does not bind O-desulfated heparin efficiently. These results suggest that the mechanism by which heparin modulates the binding of VEGF165 to the VEGF receptors may require an interaction with cell surface heparin binding molecules.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522446     DOI: 10.1006/bbrc.1994.2329

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis.

Authors:  S M Smorenburg; R Vink; M te Lintelo; W Tigchelaar; A Maas; H R Büller; C J van Noorden
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

2.  A biomimetic collagen/heparin multi-layered porous hydroxyapatite orbital implant for in vivo vascularization studies on the chicken chorioallantoic membrane.

Authors:  Kai Jin; Xin Ye; Sha Li; Bo Li; Caiqiao Zhang; Changyou Gao; Juan Ye
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-02       Impact factor: 3.117

3.  Wavy small-diameter vascular graft made of eggshell membrane and thermoplastic polyurethane.

Authors:  Shujie Yan; Brett Napiwocki; Yiyang Xu; Jue Zhang; Xiang Zhang; Xiaofeng Wang; Wendy C Crone; Qian Li; Lih-Sheng Turng
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2019-10-22       Impact factor: 7.328

Review 4.  Biological properties of VEGF/VPF receptors.

Authors:  B I Terman; M Dougher-Vermazen
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

5.  Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas.

Authors:  E Hatva; T Böhling; J Jääskeläinen; M G Persico; M Haltia; K Alitalo
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 6.  Design of growth factor sequestering biomaterials.

Authors:  David G Belair; Ngoc Nhi Le; William L Murphy
Journal:  Chem Commun (Camb)       Date:  2014-09-03       Impact factor: 6.222

7.  Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides.

Authors:  Wenjing Zhao; Scott A McCallum; Zhongping Xiao; Fuming Zhang; Robert J Linhardt
Journal:  Biosci Rep       Date:  2012-02       Impact factor: 3.840

8.  2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis.

Authors:  K Norrby
Journal:  Int J Exp Pathol       Date:  2000-06       Impact factor: 1.925

9.  Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.

Authors:  Dong Yun Lee; Sung Won Lee; Sang Kyoon Kim; Myungjin Lee; Hyo Won Chang; Hyun Tae Moon; Youngro Byun; Sang Yoon Kim
Journal:  Pharm Res       Date:  2009-10-15       Impact factor: 4.200

10.  The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.

Authors:  I Debergh; N Van Damme; P Pattyn; M Peeters; W P Ceelen
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.